Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: A randomized phase II study

Journal of Clinical Oncology

Volumn 23, Issue 3, 2005, Pages 494-501

  Thuss Patience, Peter C ^a   Kretzschmar, Albrecht ^a   Repp, Michael ^a   Kingreen, Dorothea ^a   Hennesser, Dirk ^a   Micheel, Simone ^a   Pink, Daniel ^a   Scholz, Christian ^a   Dörken, Bernd ^a   Reichardt, Peter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALIZAPRIDE; CISPLATIN; DEXAMETHASONE; DOCETAXEL; EPIRUBICIN; FLUOROURACIL; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT; DF PROTOCOL; FPEPIR REGIMEN; TAXOID;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; CANCER GROWTH; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG SAFETY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEARING IMPAIRMENT; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ADENOCARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TUMOR REGRESSION; VOMITING; ADENOCARCINOMA; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; STOMACH TUMOR; SURVIVAL; TREATMENT OUTCOME;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE PROGRESSION; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 20044393181     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.163     Document Type: Article

References (30)

1. Wilke H, Korn M, Köhne C, et al: Phase II results of weekly infusional high-dose FU (HD-FU) plus folinic acid (FA) and biweekly cisplatin (C) for advanced gastric cancer. Ann Oncol 7:46, 1996(suppl 5)
2. Rougier P, Ducreux M, Mahjoubi M, et al: Efficacy of combined 5-fluorouracil and cisplatinum in advanced gastric carcinoma: A phase II trial with prognostic factor analysis. Eur J Cancer 30A: 1263-1269, 1994
3. Webb A, Cunningham D, Scarffe JH, et al: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 15:261-267, 1997
4. Ross P, Cunningham D, Scarffe H, et al: Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. Proc Am Soc Clin Oncol 18:272a, 1999 (abstr 1042)
5. Ajani JA, Baker J, Pisters PW, et al: CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: Results of a phase II study. Cancer 94:641-646, 2002
6. Pozzo C, Bugat R, Peschel C, et al: Irinotecan in combination with CDDP or 5-FU and folinic acid is active in patients with advanced gastric or gastro-oesophageal junction adenocarcinoma: Final results of a randomised phase II study. Proc Am Soc Clin Oncol 20:134a, 2001 (abstr 531)
7. Al-Batran SE, Atmaca A, Hegewisch-Becker S, et al: Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer. J Clin Oncol 22:658-663, 2004
8. Artru P, André T, Tigaud JM, et al: Oxaliplatin (OXA), 5-fluoro-uracil (FU) and folinic acid (FA) (FOLFOX 6) in advanced/metastatic gastric carcinoma (A/MGC) patients (Pts): Final results of a multicenter phase II study. Proc Am Soc Clin Oncol 20:164a, 2001 (abstr 654)
9. Taguchi T, Sakata Y, Kanamaru R, et al: Late phase II clinical study of RP56976 (docetaxel) in patients with advanced/recurrent gastric cancer: A Japanese Cooperative Study Group trial (group A). Gan To Kagaku Ryoho 25:1915-1924, 1998
10. Mavroudis D, Kouroussis CH, Androulakis N, et al: Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF). Am J Clin Oncol 23: 341-344, 2000
11. Sulkes A, Smyth J, Sessa C, et al: Docetaxel (Taxotere) in advanced gastric cancer: Results of a phase II clinical trial-EORTC Early Clinical Trials Group. Br J Cancer 70:380-383, 1994
12. Einzig AI, Neuberg D, Remick SC, et al: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 13:87-93, 1996
13. Vanhoefer U, Wilke H, Harstrick A, et al: Phase II study of docetaxel as second line chemotherapy (CT) in metastatic gastric cancer. Proc Am Soc Clin Oncol 18:303a, 1999 (abstr 1163)
14. Roth AD, Maibach R, Martinelli G, et al: Docetaxel (Taxotere)-cisplatin (TC): An effective drug combination in gastric carcinoma-Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol 11:301-306, 2000
15. Ajani JA, Fodor M, Van Cutsem E, et al: Multinational randomized phase II trial of docetaxel (T) and cisplatin (C) with or without 5-fluorouracil (FU) in patients (Pts) with advanced gastric or GE junction adenocarcinoma (AGC-AGEJC). Proc Am Soc Clin Oncol 19:247a, 2000 (abstr 957)
16. Roth AD, Maibach R, Morant R, et al: 5-FU in protracted continuous IV infusion (5-FUpiv) can be added to Taxotere-cisplatin (TC) without dose-reduction of TC in advanced gastric carcinoma (AGC). Proc Am Soc Clin Oncol 18:245a, 1999 (abstr 943)
17. Roth AD, Ajani J: Docetaxel-based chemotherapy in the treatment of gastric cancer. Ann Oncol 14:41-44, 2003 (suppl 2)
18. Ajani JA, Van Cutsem E, Moiseyenko V, et at: Docetaxel (D), cisplatin, 5-fluorouracil compare to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial (V325). Proc Am Soc Clin Oncol 22:249a, 2003 (abstr 999)
19. Moynihan T, Hansen R, Anderson T, et al: Continuous 5-fluorouracil infusion in advanced gastric carcinoma. Am J Clin Oncol 11:461-464, 1988
20. Cocconi G, DeLisi V, Di Blasio B: Randomized comparison of 5-FU alone or in combination with mitomycin and cytarabine (MCF) in the treatment of advanced gastric cancer. Cancer Treat Rep 66:1263-1266, 1982
21. Vanhoefer U, Rougier P, Wilke H, et al: Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648-2657, 2000
22. Burris HA: Docetaxel in combination with fluorouracil for advanced solid tumors. Oncology (Huntingt) 11:50-52, 1997 (suppl 8)
23. Tubiana-Mathieu N, Merrouche Y, Cupissol D, et al: A phase II study of docetaxel (Taxotere) (TXT) in metastatic or recurrent squamous cell carcinoma (SCO of the head and neck. Proc Am Soc Clin Oncol 17:412a, 1998 (abstr 1587)
24. Constenla M, Garcia-Arroyo R, Lorenzo I, et al: Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: Results of a phase II study. Gastric Cancer 5:142-147, 2002
25. Chun HG, Puccio CA, Mittelman A: Weekly docetaxel and continuous infusion (CI) 5-fluorouracil (5-FU) in elderly patients (pts) with cancer of the stomach and distal esophagus. Proc Am Soc Clin Oncol 20:162a, 2001 (abstr 645)
26. Meta-Analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16:301-308, 1998
27. World Health Organization: WHO Hand-book for Reporting Results of Cancer Treatment. Geneva, Switzerland, World Health Organization, WHO Offset Publication No. 48, 1979
28. Simon R: Optimal two-stage design for phase II clinical trials. Control Clin Trials 10:1-10, 1989
29. Hawkins R, Cunningham D, Soerbye H, et al: Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC). Proc Am Soc Clin Oncol 22:257a, 2003 (abstr 1032)
30. Ridwelski K, Gebauer T, Fahlke J, et al: Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer. Ann Oncol 12:47-51, 2001